Elaine M Craig

TL;DR: In the early phases of the UK COVID-19 outbreak, in the absence of clear evidence about the risks for people with multiple sclerosis (pwMS) and those taking immunomodulatory disease-modifying therapies (DMT), a community-based study was launched to capture the picture of CO VID-19 among pwMS and their risk of contracting the disease.

TL;DR: In this article, the authors examined how hospital admission and mortality are affected by disability, age and disease modifying treatments (DMTs) in people with Multiple Sclerosis with COVID-19.

TL;DR: This study validates a computer-based alternative to the SDMT that enables accurate recording of elements of cognition relevant in MS but offers additional metrics that may offer further value to clinicians and people with MS.

TL;DR: Only age remained as a marker of poor outcome multivariate analysis in pwMS with COVID-19, and no MS Specific characteristics were found to be significant.

TL;DR: The results show that a patient-facing pregnancy MS registry is feasible and can collect previous adverse pregnancy outcomes, and will inform clinicians and women about the safety of DMT and adjunctive medication during pregnancy and postpartum.